cultures of primary AML samples, patient T cells induced TDCC of FLT3-positive target cells. Combination with PD-1 blockade increased BiTE activity. These data support the clinical development of an FLT3 targeting BiTE molecule for the treatment of AML.
No takes yet. Share an insight, caveat, or question.
Brauchle et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: